問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Division of Family Medicine

更新時間：2023-09-19

黃怡翔Huang, Yi-Hsiang
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

48Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃怡翔

List

94Cases

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2014-08-05 - 2018-08-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Study ended2Sites

2015-06-01 - 2018-09-30

Phase II

A Phase 2, randomized, multiple-dose, double-blind, placebo-controlled study of JKB-122 in treating subjects with non-alcoholic fatty liver disease (NAFLD)

  • Condition/Disease

    non-alcoholic fatty liver disease (NAFLD)

  • Test Drug

    JKB-122

Participate Sites
7Sites

Terminated7Sites

陳明堯
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

黃怡翔
Taipei Veterans General Hospital

2017-04-15 - 2018-08-27

Phase I

A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS

  • Condition/Disease

    HEPATITIS B VIRUS

  • Test Drug

    RO7049389

Participate Sites
7Sites

Recruiting6Sites

葉昭廷
Linkou Chang Gung Medical Foundation

2017-10-16 - 2019-05-31

Phase I

A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    CHRONIC HEPATITIS B VIRUS INFECTION

  • Test Drug

    RO7062931 sterile liquid for inection

Participate Sites
5Sites

Terminated4Sites

2013-02-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-02-01 - 2019-12-25

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2017-02-01 - 2019-06-30

Others

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

  • Condition/Disease

    The plan includes adult male and female CHB subjects aged 18 to 70 (inclusive) who are not currently receiving CHB treatment. Part 1 (Groups A, B, C, and D) will include HBeAg-positive subjects, while Part 1 (Group C1) will include HBeAg-negative subjects. After completing part 1 of the administration (after reviewing the safety, tolerability, PK and PD differences between HBeAg status), the specific CHB group included in part 2 will be determined

  • Test Drug

    GSK3389404

Participate Sites
9Sites

Recruiting8Sites

2013-02-07 - 2020-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 5 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB